www.whatisindia.com
What Is India News Service
Tuesday, May 02, 2006

India Intelligence Report


  Inscriptions  

  Editorials 

  Opinions 

  News Analysis

  University Research


  Economy
  Places
  States

  Links


Sources
 I want News  I'm a Researcher I'm a Policy Maker I'm a Traveler |  I'm an Investor  | I'm an Activist | I'm a Student
 

Indian Pharma Companies Lead M&A Numbers

 

According to a Goldman Sachs study, Indian pharmaceutical companies are leading in the number of Mergers & Acquisitions of generic industries figuring as buyers in 4 of the 7 deals worldwide. While the number of acquisitions is more, the value of these acquisitions is only USD 1 billion—small in international investment banking terms. Dr. Reddy’s Laboratories acquisition of Betapharm was the largest acquisition valued at USD 570 million.

Analysts believe there is global consolidation of the generic industry space started by Teva’s acquisition of Ivax and Sandoz’s acquisition of Hexal. In recent times, the other major deals are Watson’s acquisition of Andrx for USD 1.9 billion and Activis’s USD 1.8 billion bid for Pilva and Sindan. Given the high fragmentation with even the largest player, Teva, with only 19% market share and lack of global reach, analysts believe that this consolidation will continue. Many key markets such as Japan are still under-penetrated.

 

The main drivers for greater consolidation are expected to be increased scale of operations, market share, enhanced geographical presence, access to newer technologies, and economies of scale.

Indian companies are expected to be more aggressive buyers of companies in Europe in the short run because US companies are considered over-priced. Analysts say that they would most likely take a product alliance route to expand market-share in the US. The only exception to this view are Sun and Wockhardt, which have announced plans to buy US based companies. Additionally, there is intense pricing and margin pressure in the US making it less attractive than the smaller but bigger bang-for-the-buck European deals.

The overwhelming consensus is that the next Indian buy will most likely happen in France thereby giving it access to underlying registrations across Europe and establish a pan-European presence.


© 2005 Copyright What Is India Publishers (P) Ltd. All Rights Reserved.